Scholars Central

PerspectivePublished 2023

Rare Cancers and Clinical Trials Progress in the Face of Rarity

Authors: Senapati Dulal

Journal of Cancer Clinical Trials

Volume 8 · Issue 3 · Pages 1–2

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Cancer is a formidable adversary, affecting millions of lives worldwide. While common cancers like breast, lung and prostate cancers dominate the public health landscape, there exists a group of malignancies that are far less prevalent but equally devastating - rare cancers. These rare cancers pose unique challenges for both patients and healthcare providers. However, there is hope on the horizon, as clinical trials are making significant progress in the face of rarity, offering new possibilities for those affected by these less common but often aggressive diseases. Rare cancers, also known as orphan cancers, are those with a lower incidence compared to more prevalent malignancies. Although no universal consensus defines the threshold for rarity, the American Cancer Society suggests that cancers with an incidence of fewer than six cases per 100,000 people per year fall into this category. Some examples of rare cancers include cholangiocarcinoma (bile duct cancer), mesothelioma and sarcomas.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Cancer Clinical Trials.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Cancer Clinical Trials
  • SubjectOncology & Cancer
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Senapati Dulal”